Tag Archives: treatment

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis.

Posted on by

“Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) [Sativex®] is an oromucosal spray formulation that contains principally THC and CBD at an approximately 1:1 fixed ratio, derived from cloned Cannabis sativa L. plants.

The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2)…

THC/CBD is approved in a number of countries, including Germany and the UK, as an add-on treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.

In the largest multinational clinical trial that evaluated the approved THC/CBD regimen in this population, 12 weeks’ double-blind treatment with THC/CBD significantly reduced spasticity severity (primary endpoint) compared with placebo in patients who achieved a clinically significant improvement in spasticity after 4 weeks’ single-blind THC/CBD treatment, as assessed by a patient-rated numerical rating scale.

A significantly greater proportion of THC/CBD than placebo recipients achieved a ≥30 % reduction (a clinically relevant reduction) in spasticity severity. The efficacy of THC/CBD has been also shown in at least one everyday clinical practice study (MOVE 2). THC/CBD was generally well tolerated in clinical trials. Dizziness and fatigue were reported most frequently during the first 4 weeks of treatment and resolved within a few days even with continued treatment.

Thus, add-on THC/CBD is a useful symptomatic treatment option for its approved indication.”

http://www.ncbi.nlm.nih.gov/pubmed/24671907

The Health Benefits of Medical Cannabis

Posted on by

marijuanaplant

“Few people may know this but cannabis, or marijuana, had been popular as a remedy since ancient times.

It was in 2727 B.C. when there was the first record of its use in China. It was also familiar to ancient Greeks, Romans and people from the Middle East.

It was only during 1600 when cannabis use began to be regulated and restricted…

It was only recently that the public knew that cannabis has many benefits which were previously unknown to many people. Cannabis has been legalized in some states because it is non-toxic, can be moderately used by adults and has some beneficial effects on health.

Medical Cannabis

Medical cannabis is the term used to refer to the use of marijuana, cultivated with medical seeds, and other cannabinoid substances for treating health problems. Marijuana is a mixture of green, brown, crumpled and dried leaves from the marijuana plant. This mixture of leaves are rolled up and smoked like a cigar or cigarette or smoked through a pipe. It can also be mixed with food and eaten. Its mode of administration to the user includes vaporizing or smoking dried buds, consuming extracts and the ingestion of capsules. Synthetic cannabinoids are even available in some countries such as dronabinol and nabilone. While in some countries the recreational use of marijuana is illegal, in some countries its medical use is legal.”

http://www.doctortipster.com/19879-the-health-benefits-of-medical-cannabis.html

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

Posted on by

“…exogenous CB1agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease… Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.

The results of this study are important because they suggest that in addition to symptom management, cannabinoids offer the potential to slow the progression of a disease that as yet has no satisfactory treatment.”

http://brain.oxfordjournals.org/content/126/10/2191.full

Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Posted on by

“Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain) (Level A). Clinicians might offer tetrahydrocannabinol for spasticity symptoms and pain (excluding central neuropathic pain) (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity (short-term)/tremor (Level B) and possibly effective for spasticity and pain (long-term) (Level C). Clinicians might offer Sativex oromucosal cannabinoid spray (nabiximols) for spasticity symptoms, pain, and urinary frequency (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity/urinary incontinence (Level B). Clinicians might choose not to offer these agents for tremor (Level C). Clinicians might counsel patients that magnetic therapy is probably effective for fatigue and probably ineffective for depression (Level B); fish oil is probably ineffective for relapses, disability, fatigue, MRI lesions, and quality of life (QOL) (Level B); ginkgo biloba is ineffective for cognition (Level A) and possibly effective for fatigue (Level C); reflexology is possibly effective for paresthesia (Level C); Cari Loder regimen is possibly ineffective for disability, symptoms, depression, and fatigue (Level C); and bee sting therapy is possibly ineffective for relapses, disability, fatigue, lesion burden/volume, and health-related QOL (Level C)…”

http://www.ncbi.nlm.nih.gov/pubmed/24663230

AAN calls oral cannabinoids effective for MS pain, spasticity

Posted on by

“An expert panel organized by the American Academy of Neurology called oral cannabis extract the only complementary and alternative medicine unequivocally effective for helping patients with multiple sclerosis, specifically easing their pain and symptoms of spasticity, medicine possibly for as long as 1 year of treatment.”

http://www.clinicalpsychiatrynews.com/cme/click-for-credit-articles/single-article/aan-calls-oral-cannabinoids-effective-for-ms-pain-spasticity/6ca42663d197581d76107390a304ec4d.html

Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis

Posted on by

“Controlled trial shows improved spasticity, reduced pain after smoking medical marijuana

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity – a common and disabling symptom of this neurological disease.”

http://health.ucsd.edu/news/releases/Pages/2012-05-14-smoked-cannabis-reduces-symptoms-of-multiple-sclerosis.aspx

Medical marijuana

“Medical marijuana eases some MS symptoms, neurologists report” http://www.latimes.com/science/sciencenow/la-sci-sn-treating-ms-with-cannabis-20140324,0,2596095.story

Medical Marijuana Pills May Ease Some MS Symptoms: Review

Posted on by

Medical Marijuana Pills May Ease Some MS Symptoms: Review

“Medical marijuana pills and sprays might ease the symptoms of multiple sclerosis, but most other alternative therapies do little to lessen the pain and muscle rigidity that often accompanies the disease, according to new guidelines.

To reach that conclusion, an expert panel from the American Academy of Neurology reviewed more than 40 years of research on alternative medicine treatments for multiple sclerosis (MS)…

The guidelines are published in the March 25 issue of the journal Neurology.”

http://consumer.healthday.com/public-health-information-30/marijuana-news-759/guideline-medical-marijuana-may-ease-some-ms-symptoms-686096.html#.UzDKXsAnP9M.twitter

“Marijuana May Ease Some Symptoms of MS, New Guidelines Find. Medical marijuana pills or an oral spray made from cannabis may help ease some of the painful spasms caused by multiple sclerosis that make day-to-day life hard for patients, according to new guidelines from the American Academy of Neurology.” http://www.nbcnews.com/health/health-news/marijuana-may-ease-some-symptoms-ms-new-guidelines-find-n60626


Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.

Posted on by

“Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the major psychoactive constituent of Cannabis sativa L., has been widely studied for its potential pharmaceutical application in the treatment of various diseases and disturbs.

The aim of this work was to develop a stable aqueous Delta(9)-THC formulation acceptable for different ways of administration, and to evaluate the therapeutic properties of the new Delta(9)-THC based preparation for pain treatment.

Significant antinociceptive activity has been detected by both intraperitoneal and intragastric administration of the new Delta(9)-THC pharmaceutical preparation.”

http://www.ncbi.nlm.nih.gov/pubmed/20399844

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model.

Posted on by

“Experimental animal models of migraine have suggested the existence of interactions between the endocannabinoid system and pain mediation in migraine.

Extensive evidence has demonstrated a role for the cannabinoid-1 (CB1) receptor in antinociception.

…recent research suggests that also CB2 receptors, especially located outside the central nervous system, play a role in the perception of pain…

In this study we evaluated the role of CB2 receptors in two animal models of pain that may be relevant for migraine…

CONCLUSION:

These findings suggest that the pharmacological manipulation of the CB2 receptor may represent a potential therapeutic tool for the treatment of migraine.”

http://www.ncbi.nlm.nih.gov/pubmed/24636539

CB2 cannabinoid receptor mediation of antinociception.

Posted on by

“Management of acute pain remains a significant clinical problem. In preclinical studies, CB2 cannabinoid receptor-selective agonists inhibit nociception without producing central nervous system side effects.

The experiments reported here further test the hypothesis that CB2 receptor activation inhibits nociception…

The CB2 receptor-selective agonist produces antinociceptive… activation of CB2 receptors results in antinociception…

…confirm the potential therapeutic relevance of CB2 cannabinoid receptors for the treatment of acute pain.”

http://www.ncbi.nlm.nih.gov/pubmed/16563625